Abstract P3-09-09: Eribulin mesylate plus capecitabine for adjuvant treatment in post-menopausal ER+ early-stage breast cancer: A phase 2, multicenter, open-label study using 2 different dosage regimens

Abstract OT-32-01: A phase 2, open-label study of bintrafusp alfa monotherapy in patients withHMGA2-expressing triple-negative breast cancer

10.1158/1538-7445.sabcs20-ot-32-01 ◽

2021 ◽

Author(s):

Leisha A Emens ◽

Margaret E. Gatti-Mays ◽

Joyce O’Shaughnessy ◽

Luc Dirix ◽

Giovanni Faggioni ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Abstract P1-13-11: Adjuvant treatment of early-stage breast cancer with eribulin mesylate following dose-dense doxorubicin and cyclophosphamide: preliminary results from a phase 2, single-arm feasibility study

10.1158/0008-5472.sabcs12-p1-13-11 ◽

2012 ◽

Author(s):

TA Traina ◽

C Hudis ◽

M Fornier ◽

D Lake ◽

R Lehman ◽

...

Keyword(s):

Breast Cancer ◽

Feasibility Study ◽

Adjuvant Treatment ◽

Early Stage ◽

Early Stage Breast Cancer ◽

Phase 2 ◽

Eribulin Mesylate ◽

Preliminary Results ◽

Dose Dense

Abstract OT1-01-04: A phase 2, open-label study of imprime PGG (Imprime), a novel beta glucan, with pembrolizumab (Pembro) in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

10.1158/1538-7445.sabcs17-ot1-01-04 ◽

2018 ◽

Cited By ~ 1

Author(s):

SJ O'Day ◽

AT Stopeck ◽

RD Huhn ◽

MA Gargano ◽

R Prathikanti ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 2 ◽

Open Label ◽

Beta Glucan ◽

Open Label Study ◽

Abstract P3-09-04: Phase 2, open-label study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC) (KEYNOTE- 890/OMS-I141)

10.1158/1538-7445.sabcs19-p3-09-04 ◽

2020 ◽

Author(s):

Melinda L. Telli ◽

Irene Wapnir ◽

Bianca Devitt ◽

Katharine Cuff ◽

Hatem Soliman ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

1889 Prospective, non-randomised, open-label study of UDPgluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics (PK) in post-menopausal hormone receptor (HR)-positive Asian metastatic breast cancer (MBC) patients progressing after prior endocrine therapy

European Journal of Cancer ◽

10.1016/s0959-8049(16)30839-5 ◽

2015 ◽

Vol 51 ◽

pp. S295-S296

Author(s):

A. Wong ◽

L.Z. Wang ◽

F.C. Wong ◽

S. Ow ◽

K. Nesaretnam ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Metastatic Breast ◽

Predictive Marker ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Post Menopausal

Abstract P6-11-03: A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs16-p6-11-03 ◽

2017 ◽

Author(s):

IA Mayer ◽

CL Arteaga ◽

R Nanda ◽

KD Miller ◽

K Jhaveri ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Abstract P1-12-05: Phase 2 study of dose-dense doxorubicin and cyclophosphamide followed by eribulin mesylate with or without prophylactic growth factor for adjuvant treatment of early-stage breast cancer

10.1158/1538-7445.sabcs15-p1-12-05 ◽

2016 ◽

Author(s):

K Cadoo ◽

PA Kaufman ◽

C Hudis ◽

C Chang ◽

E Berrak ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Adjuvant Treatment ◽

Early Stage ◽

Early Stage Breast Cancer ◽

Phase 2 ◽

Eribulin Mesylate ◽

Phase 2 Study ◽

Dose Dense

Abstract GS1-03: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01)

10.1158/1538-7445.sabcs19-gs1-03 ◽

2020 ◽

Cited By ~ 1

Author(s):

Ian E Krop ◽

Cristina Saura ◽

Toshinari Yamashita ◽

Yeon Hee Park ◽

Sung-Bae Kim ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Previously Treated

monarcHER: A phase 2 randomized open-label study of abemaciclib plus trastuzumab (T) with or without fulvestrant (F) compared to standard-of-care chemotherapy of physician's choice plus T in women with HR +, HER2+ advanced breast cancer

Annals of Oncology ◽

10.1093/annonc/mdw365.93 ◽

2016 ◽

Vol 27 ◽

pp. vi99 ◽

Cited By ~ 1

Author(s):

S.M. Tolaney ◽

N. Bourayou ◽

S. Goel ◽

T. Forrester ◽

F. André

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Standard Of Care ◽

Advanced Breast ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

P3-16-18: Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients with Previously Treated Metastatic Breast Cancer.

10.1158/0008-5472.sabcs11-p3-16-18 ◽

2011 ◽

Author(s):

JA O'Shaughnessy ◽

CRC Osborne ◽

MA Steinberg ◽

FA Holmes ◽

HS Kim ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Previously Treated